[1] Estcourt LJ, Birchall J, Allard S, et al.Guidelines for the use of platelet transfusions[J]. Br J Haematol,2017,176(3):365-394.
[2] Stanworth SJ, Estcourt LJ, Powter G, et al.A no-prophylaxis platelet-transfusion strategy for hematologic cancers[J]. N Engl J Med,2013,368(19):1771-1780.
[3] Crighton GL, Estcourt LJ, Wood EM, et al. A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation[J]. Cochrane Database Syst Rev,2015,(9):CD010981.
[4] Estcourt LJ, Stanworth SJ, Murphy MF.Platelet transfusions for patients with haematological malignancies: who needs them?[J]. Br J Haematol,2011,154(4):425-440.
[5] Estcourt LJ, Stanworth S, Doree C, et al. Different doses of prophylactic platelet transfusion for preventing blee-ding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation[J]. Cochrane Database Syst Rev,2015,(10):CD010984.
[6] Estcourt LJ, Birchall J, Lowe D, et al.Platelet transfusions in haematology patients: are we using them appropriately?[J]. Vox Sang,2012,103(4):284-293.
[7] Schiffer CA, Anderson KC, Bennett CL, et al.Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology[J]. J Clin Oncol,2001,19(5):1519-1538.
[8] Liumbruno G, Bennardello F, Lattanzio A, et al.Recommendations for the transfusion of plasma and platelets[J]. Blood Transfus,2009,7(2):132-150.
[9] Kaufman RM, Djulbegovic B, Gernsheimer T, et al.Platelet transfusion: a clinical practice guideline from the AABB[J]. Ann Intern Med,2015,162(3):205-213.
[10] Zhu MS, Chen JZ, Xu AP.Factors that can minimize bleeding complications after renal biopsy[J]. Int Urol Nephrol,2014,46(10):1969-1975.
[11] Hedges SJ, Dehoney SB, Hooper JS, et al.Evidence-based treatment recommendations for uremic bleeding[J]. Nat Clin Pract Nephrol,2007,3(3):138-153.
[12] Manno C, Bonifati C, Torres DD, et al.Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial[J]. Am J Kidney Dis,2011, 57(6):850-855.
[13] Spahn DR, Bouillon B, Cerny V, et al.Management of bleeding and coagulopathy following major trauma: an updated European guideline[J]. Crit Care,2013,17(2):R76.
[14] Vassallo R, Bachowski G, Benjamin RJ, et al.A compendium of transfusion pratice guidelines[R]. American Red Cross,2013.
[15] Hunt BJ, Allard S, Keeling D, et al.A practical guideline for the haematological management of major haemorrhage[J]. Br J Haemato,2015,170(6):788-803.
[16] Watson H, Davidson S, Keeling D, et al.Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition[J]. Br J Haematol,2012,159(5):528-540.
[17] Bolton-Maggs PH.Bullet points from SHOT: key messages and recommendations from the Annual SHOT Report 2013[J]. Transfus Med,2014,24(4):197-203.
[18] Scully M, Hunt BJ, Benjamin S, et al.Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies[J]. Br J Haematol,2012,158(3):323-335.
[19] Dunbar NM, Ornstein DL, Dumont LJ.ABO incompatible platelets: risks versus benefit[J]. Curr Opin Hematol,2012,19(6):475-479.
[20] Dunbar NM, Katus MC, Freeman CM, et al.Easier said than done: ABO compatibility and D matching in apheresis platelet transfusions[J]. Transfusion,2015,55(8):1882-1888.
[21] Valsami S, Dimitroulis D, Gialeraki A, et al.Current trends in platelet transfusions practice: The role of ABO-RhD and human leukocyte antigen incompatibility[J]. Asian J Transfus Sci,2015,9(2):117-123.
[22] Cid J, Lozano M, Ziman A, et al, Low frequency of anti-D alloimmunization following D+ platelet transfusion: the Anti-D Alloimmunization after D-incompatible Platelet Transfusions (ADAPT) study[J]. Br J Haematol,2015,168(4):598-603.
[23] Yanagisawa R, Shimodaira S, Kojima S, et al.Replaced platelet concentrates containing a new additive solution, M-sol: safety and efficacy for pediatric patients[J]. Transfusion,2013,53(9):2053-2060.
[24] Killick SB, Carter C, Culligan D, et al.Guidelines for the diagnosis and management of adult myelodysplastic syndromes[J]. Br J Haematol,2014,164(4):503-525.
[25] Mahévas M, Fain O, Ebbo M, et al.The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study[J]. Br J Haematol,2014,165(6):865-869.
